Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial. // The Lancet. – URL: https://www.sciencedirect.com/science/article/pii/S0140673626019537?dgcid=rss_sd_all
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial. The Lancet. https://www.sciencedirect.com/science/article/pii/S0140673626019537?dgcid=rss_sd_all
“Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.” The Lancet.
@article{article68520,
title = {Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial},
journal = {The Lancet},
url = {https://www.sciencedirect.com/science/article/pii/S0140673626019537?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...